Cerenome has filed a notice of an exempt offering of securities to raise $20 Million in New Funding.

According to filings with the U.S. Securities and Exchange Commission, Cerenome is raising up to $20,000,000.00 in new funding. The federal securities law requires the notice to be filed by companies that have sold securities without registration under the Securities Act of 1933 in an offering made under Rule 504 or 506 of Regulation D or Section 4(a)(5) of the Securities Act. A company must file this notice within 15 days after the first sale of securities in the offering. For this purpose, the date of first sale is the date on which the first investor is irrevocably contractually committed to invest. Each issuer of securities that sells its securities in reliance on an exemption provided in Regulation D or Section 4(a)(5) of the Securities Act of 1933 must file this notice containing the information requested with the U.S. Securities and Exchange Commission (SEC) and with the state(s) requiring it. If more than one issuer has sold its securities in the same transaction, all issuers should be identified in this filing with the SEC.

About Cerenome
Cerenome is a CNS oncology company developing an integrated platform that combines precision diagnostics, targeted therapeutics, and clinical data to improve how central nervous system cancers are detected, treated, and understood. Its CNSide diagnostic technology detects, characterizes, and monitors CNS cancer using cerebrospinal fluid, with detection and monitoring and molecular profiling listed as commercial capabilities. The company is also developing REYOBIQ, a portfolio of targeted radiotherapeutics designed to reach cancers that conventional therapies may not, with clinical programs spanning recurrent glioblastoma, leptomeningeal metastases, and pediatric ependymoma and high-grade glioma. Cerenomes clinical intelligence platform uses clinical data and artificial intelligence to generate insights intended to improve future patient care. The company states that its work builds on efforts that began at Plus Therapeutics in 2020, with hundreds of evaluated patients, ongoing clinical trials, and peer-reviewed publications supporting its approach.

To learn more, visit https://cerenome.com/
LinkedIn: https://www.linkedin.com/company/cerenome-cns/

Contact:
Andrew Sims, Chief Financial Officer
https://www.linkedin.com/in/andrew-sims-0302195/

SOURCE: http://www.intelligence360.io
Copyright (c) 2026 SI360 Inc. All rights reserved.